Home      Login


Psychiatric Disorders, Antipsychotic Usage and Comorbid Diabetes Mellitus  


Author:  Patrick A.  Toalson, R.Ph., BCPP.; Leslie M.  Schuh, Ph.D..; John P.  Houston, M.D., Ph.D..


Source: Volume 05, Number 04, May/June 2004 , pp.37-42(6)




Correctional Health Care Report

< previous article |next article > |return to table of contents

Abstract: 

Psychiatric disorders are prevalent among inmates in correctional settings. Over the past decade atypical antipsychotics have become more important in the treatment of patients with psychosis- related disorders such as schizophrenia. Atypical antipsychotics have superior clinical efficacy, a better safety profile regarding extrapyramidal symptoms, and prolactin levels are generally lower in patients treated with most atypical antipsychotic agents compared to the conventional antipsychotics used in clinical practice since the 1950s. Despite this overall superior safety profile, some have raised concerns regarding possible associations with various metabolic disruptions including weight gain, hyperglycemia and diabetes. There is debate questioning what relationship exists, if any, between hyperglycemia and diabetes in patients with serious mental illnesses and the use of antipsychotic treatments.

Keywords: Epidemiological Studies, insulin, aripiprazole, haloperidol, olanzapine

Affiliations:  1: Eli Lilly; 2: Eli Lilly; 3: Eli Lilly.

Subscribers click here to open full text in PDF.
Non-subscribers click here to purchase this article. $15

< previous article |next article > |return to table of contents